Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    cardioxyl
Show Display Options
Rank Status Study
1 Completed A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers
Condition: Heart Failure
Interventions: Drug: CXL-1427 Ascending Dose;   Other: Placebo;   Drug: CXL-1427 Descending Dose
2 Completed A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
Conditions: Heart Failure;   Decompensated Heart Failure;   Acute Heart Failure
Interventions: Drug: CXL-1427;   Drug: Placebo
3 Completed An Observational Study of the Functional Capacity of Heart Failure
Condition: Acute Heart Failure
Intervention: Procedure: 6 Minute Walk Test
4 Completed Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure
Condition: Heart Failure
Interventions: Drug: CXL-1020;   Drug: Placebo for CXL-1020 Cohort 1;   Drug: Placebo for CXL-1020 Cohort 2;   Drug: CXL-1020 Dose for Echo Cohort A;   Drug: CXL-1020 Doses for Echo Cohort B
5 Completed A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure
Condition: Heart Failure
Interventions: Drug: Placebo;   Drug: Strata 1 CXL-1020;   Drug: Strata 2 CXL-1020;   Drug: Strata 3 CXL-1020

Study has passed its completion date and status has not been verified in more than two years.